Lophora Announces First Subjects Dosed in Phase 1 Clinical Trial of LPH-5
Lophora ApS, a Danish biotech company focused on next-generation psychedelic therapies for central nervous system disorders, today announced that the
Lophora Successfully Completes $3M Financing to Propel Phase I Trials for Lead CNS Drug LPH-5
After receiving approval from the European Medicines Agency (EMA) to commence its Phase I clinical study for LPH-5, Lophora has
Lophora Receives Approval from EMA to Initiate Phase I Clinical Trial for LPH-5, a Promising Treatment for Depression.
Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2AR therapeutics to treat psychiatric disorders, announced today that
Lophora Submits Clinical Trial Authorisation (CTA) Application to the French Medicines Agency (ANSM) for lead CNS drug LPH-5.
Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2ARA medicines to treat a multitude of psychiatric disorders,
Structure-Activity Relationships of Lophora’s selective serotonin 5-HT2A receptor agonists published in the Journal of Medicinal Chemistry
The Lophora team has published a paper detailing the discovery and structure of the lead clinical candidate LPH-5 in the
Lophora Closes Bridge Round to Strengthen Global Patent Portfolio and prepare for Phase I
Founded by initial investments from BII (Novo Nordisk Foundation), Vækstfonden (EIFO) and Innovation Fund Denmark, Lophora has received additional support
Lophora completes preclinical development of LPH-5 for treatment-resistant depression
Lophora has completed the pre-clinical development of its first-in-class lead candidate LPH-5 for Treatment Resistant Depression. No toxicology or histopathology
Lophora enters Research Collaboration with Beckley Psytech
Lophora and Beckley Psytech Limited, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of
Lophora Receives Additional Funding to Complete Pre-Clinical Development of LPH-5 – A Novel and Innovative Agent to Address Treatment-Resistant Depression
Founded by an initial investment of US$1.8M from the BioInnovation Institute (a Novo Nordisk Foundation Initiative), Lophora has received additional
Lophora Initiates Preclinical Development of LPH-5 for Treatment-Resistant Depression
Lophora has been granted a $1.5M convertible loan by the Novo Nordisk Foundation to advance their first-in-class lead candidate LPH-5.
